New treatments for malaria prevention and management
Next Generation ELQs for Treatment and Once-Monthly Protection Against Malaria
This study is working on new malaria medications that not only treat the infection quickly but also help protect people from getting malaria in the future, especially in areas where the disease is common.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11050168 on NIH RePORTER |
What this research studies
This research focuses on developing next-generation anti-malarial drugs that provide both immediate treatment and long-term protection against malaria. The approach involves creating new medications that can act quickly to eliminate the malaria parasite and also offer sustained protection for individuals at risk of malaria infection. By targeting specific stages of the parasite's lifecycle, these drugs aim to prevent outbreaks and reduce the transmission of malaria in high-risk areas. The research will utilize advanced drug formulations to enhance effectiveness and bioavailability.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals living in or traveling to malaria-endemic regions who are at risk of infection.
Not a fit: Patients who are not at risk of malaria infection or those living in malaria-free regions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments and preventive measures against malaria, significantly reducing the disease's impact on vulnerable populations.
How similar studies have performed: Previous research has shown promise in developing new anti-malarial agents, indicating that innovative approaches in this field can lead to successful outcomes.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Riscoe, Michael Kevin — Oregon Health & Science University
- Study coordinator: Riscoe, Michael Kevin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.